Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies
Open Access
- 24 March 2010
- journal article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 8 (1), 28
- https://doi.org/10.1186/1479-5876-8-28
Abstract
Background Current vaccines against HPVs are constituted of L1 protein self-assembled into virus-like particles (VLPs) and they have been shown to protect against natural HPV16 and HPV18 infections and associated lesions. In addition, limited cross-protection has been observed against closely related types. Immunization with L2 protein in animal models has been shown to provide cross-protection against distant papillomavirus types, suggesting that the L2 protein contains cross-neutralizing epitopes. However, vaccination with L2 protein or L2 peptides does not induce high titers of anti-L2 antibodies. In order to develop a vaccine with the potential to protect against other high-risk HPV types, we have produced HPV58 pseudovirions encoding the HPV31 L2 protein and compared their capacity to induce cross-neutralizing antibodies with that of HPV L1 and HPV L1/L2 VLPs. Methods The titers of neutralizing antibodies against HPV16, HPV18, HPV31 and HPV58 induced in Balb/c mice were compared after immunization with L2-containing vaccines. Results Low titers of cross-neutralizing antibodies were detected in mice when immunized with L1/L2 VLPs, and the highest levels of cross-neutralizing antibodies were observed in mice immunized with HPV 58 L1/L2 pseudovirions encoding the HPV 31 L2 protein. Conclusions The results obtained indicate that high levels of cross-neutralizing antibodies are only observed after immunization with pseudovirions encoding the L2 protein. HPV pseudovirions thus represent a possible new strategy for the generation of a broad-spectrum vaccine to protect against high-risk HPVs and associated neoplasia.Keywords
This publication has 38 references indexed in Scilit:
- Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus VaccinesJournal of Virology, 2009
- Inhibition of cervical cancer cell growth by human papillomavirus virus–like particles packaged with human papillomavirus oncoprotein short hairpin RNAsMolecular Cancer Therapeutics, 2009
- Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunityVaccine, 2008
- Arrangement of L2 within the Papillomavirus CapsidJournal of Virology, 2008
- Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2Proceedings of the National Academy of Sciences, 2008
- Detection of Human Papillomavirus Type 31-Neutralizing Antibodies from Naturally Infected Patients by an Assay Based on Intracellular Assembly of Luciferase-Expressing PseudovirionsClinical and Vaccine Immunology, 2008
- Prophylactic DNA immunization against multiple papillomavirus typesVaccine, 2007
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human PapillomavirusesJournal of Virology, 2002
- L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome EncapsidationJournal of Virology, 2001